American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Nov 2008
Comment Letter Randomized Controlled TrialMethodologic shortcomings of the INSPIRE randomized trial.
-
Am. J. Respir. Crit. Care Med. · Nov 2008
Randomized Controlled TrialDaclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.
Airway inflammation in asthma is associated with increased activated CD25(+) T cells, IL-2, and soluble IL-2 receptors (IL-2Rs). ⋯ Daclizumab improved pulmonary function and asthma control in patients with moderate to severe chronic asthma inadequately controlled on ICS. The mechanism of action likely involves inhibition of proinflammatory cytokine generation by IL-2R blockade in activated T cells. Clinical trial registered with www.clinicaltrials.gov (NCT00028288).
-
Am. J. Respir. Crit. Care Med. · Nov 2008
Randomized Controlled Trial Multicenter StudyTreatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.
An efficacious medical therapy for idiopathic pulmonary fibrosis (IPF) remains elusive. ⋯ In this exploratory study in patients with clinically progressive IPF, etanercept was well tolerated. Although there were no differences in the predefined endpoints, a decreased rate of disease progression was observed on several measures. Further evaluation of TNF antagonists in the treatment of IPF may be warranted. Clinical trial registered with www.clinicaltrials.gov (NCT 00063869).
-
Am. J. Respir. Crit. Care Med. · Nov 2008
Randomized Controlled Trial Multicenter StudyInhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis (CF) on maintenance treatment for Pseudomonas aeruginosa (PA) airway infection was evaluated in this randomized, double-blind, placebo-controlled study. ⋯ AZLI was effective in patients with CF using frequent TIS therapy. AZLI delayed time to need for inhaled or intravenous antipseudomonal antibiotics, improved respiratory symptoms and pulmonary function, and was well tolerated. Clinical trial registered with www.clinicaltrials.gov (NCT 00104520).
-
Am. J. Respir. Crit. Care Med. · Nov 2008
Randomized Controlled TrialGene expression profiles during in vivo human rhinovirus infection: insights into the host response.
Human rhinovirus infections cause colds and trigger exacerbations of lower airway diseases. ⋯ Rhinovirus infection significantly alters the expression of many genes associated with the immune response, including chemokines and antivirals. The data obtained provide insights into the host response to rhinovirus infection and identify potential novel targets for further evaluation.